Preview

Rational Pharmacotherapy in Cardiology

Advanced search

An Attempt to Accord the Quality of Therapy of Stable Coronary Heart Disease Patients with Current Clinical Guidelines (ALIGN study): Design and the First Results

https://doi.org/10.20996/1819-6446-2020-02-08

Full Text:

Abstract

Aim. To assess the quality of therapy in stable coronary heart disease (CHD) patients, who first sought consultation in the specialized cardiology department of the research center, and try to adjust the therapy in accordance with current clinical guidelines, paying special attention to achieving the target levels of blood pressure, low-density lipoprotein cholesterol (LDL), and glycosylated hemoglobin (in patients with diabetes mellitus), increasing exercise tolerance and improving the quality of life (QL).

Material and methods. The ALIGN study is an integral part of the PROFILE outpatient registry. ALIGN study included all patients with verified coronary heart disease who came for consultation to the specialized institution for the first time or for the first time in more than the last 3 years. Patients have been recruited from December 01, 2017 to December 31, 2019. The study consisted of 4 visits: the first-time visit – inclusion in the study (V0), when drug therapy, QL, and adherence were evaluated, and therapy correction was made in accordance with clinical guidelines. In 3 months (V1) the target values of clinical and laboratory parameters were estimated. The third visit (V2) was planned to take place 1 year after the first visit with reevaluation of QL and patients' adherence to treatment, and effectiveness of the therapy. The fourth visit (V3)/telephone contact was planned in 2 years after the first visit to assess life status, get information about complications and therapy.

Results. 389 people were included in the PROFILE registry for the specified period of time, 79 had a verified diagnosis of CHD, and 71 patients were included in the ALIGN study: 55 men (aged of 68.7±8.96 years) and 16 women (aged of 67.5±8.08 years). Arterial hypertension was registered in 90.1% of patients, stable angina class I-III – in 62%, 47.9% of patients had a history of acute myocardial infarction (AMI), 52.1% had percutaneous coronary intervention, 15.5% of patients had coronary artery bypass graft, chronic heart failure was detected in 40.8%, diabetes mellitus – in 21.1%, atrial fibrillation – in 15.5% of patients. Lipid-lowering drugs were taken by 53 (74.6%) patients, but only 21 (29.6%) achieved the target values of LDL cholesterol. Angiotensin-converting enzyme inhibitors were taken by 34 patients (47.9%), and angiotensin receptor blockers by 15 (21%) of patients, 47 (66.2%) patients took beta-blockers, antiplatelet agents were taken by 61 people, and anticoagulants by 10 patients. Patients who had a history of AMI had been prescribed BB in 88%, statins – in 90%, and renin-angiotensin-aldosterone system (RAAS) blockers – in 80% of cases.

Conclusions. Initial quality of therapy for patients with stable CHD did not fully match the clinical guidelines: a quarter of patients did not receive lipidlowering therapy, and target levels of LDL cholesterol were achieved only in one third of patients. Among patients who had a history of AMI, every fifth patient did not receive RAAS blockers.

About the Authors

S. Yu. Martsevich
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Sergey Yu. Martsevich – MD, PhD, Professor, Head of Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



E. D. Zharkova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Ekaterina D. Zharkova – MD, Postgraduate Student, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



N. P. Kutishenko
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Natalia P. Kutishenko – MD, PhD, Head of the Laboratory for Pharmacoepidemiological Research, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



Yu. V. Lukina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Yulia V. Lukina – MD, PhD, Leading Researcher, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



S. N. Tolpygina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Svetlana N. Tolpygina – MD, PhD, Leading Researcher, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



V. P. Voronina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Victoria P. Voronina – MD, PhD, Senior Researcher, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



A. V. Zagrebelnyy
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Alexander V. Zagrebelnyy – MD, PhD, Senior Researcher, Department of Preventive Pharmacotherapy

Petroverigsky per. 10, Moscow, 101990



References

1. Surinov A.E., Baranov E.F., Bezborodova T.S., et al. Russian Statistical Yearbook, 2018. Moscow: Rosstat; 2019 (In Russ.)

2. Members Task Force Members; Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. DOI:10.1093/eurheartj/eht296.

3. Shalnova S.A., Deev A.D. OSCAR Study lessons «EpidemiOlogy and treatment of high-riSk patients in real-world ClinicAl pRactice, 2005-2006». Cardiovascular Therapy and Prevention. 2007;6(1):4753 (In Russ.)

4. Oganov R.G., Pogosova G.V., Koltunov I.E., et al. RELIPH Regular Treatment and Prevention The Key to Improvement of Situation With Cardiovascular Diseases in Russia: Results of a Russian Multicenter Study (Part III). Kardiologiia. 2008;48(4):46-53 (In Russ.)

5. Pogosova G.V., Koltunov I.E., Melik-Ogandzhanyan G.Y., Sokolova O.Y. Compliance to cardiovascular treatment: clinicians and patients’ problem. Cardiovascular Therapy and Prevention. 2009;8(4):98102 (In Russ.)

6. Erlikh A.D., Gratsiansky N.A. Registry of Acute Coronary Syndromes RECORD. Characteristics of Patients and Results of Inhospital Treatment. Kardiologiia. 2009;49(7-8):4-12 (In Russ.)

7. Shalnova S.A., Deev A.D., Karpov Y.A. Arterial hypertension and coronary heart disease in real-world cardiology practice. Cardiovascular Therapy and Prevention. 2006;5(2):73-80 (In Russ.)

8. Tolpygina S.N., Polyanskaya Y.N., Martsevich S.Y. Treatment of patients with chronic ischemic heart daisease in real clinical practice according to the data from PROGNOZ IBS register (Part 1). Rational Pharmacotherapy in Cardiology. 2013;9(2):138-42. (In Russ.) DOI:10.20996/1819-6446-2013-9-2-138-142.

9. Lukina Y.V., Kutishenko N.P., Dmitrieva N.A., Martsevich S.Y. Compliance to Clinical prescriptions in ischemic heart disease patients (by the data from outpatient registry PROFILE) Russian Journal of Cardiology. 2017;(3):14-9 (In Russ.) DOI:10.15829/1560-4071-2017-3-14-19.

10. Boytsov S.A., Yakushin S.S., Martsevich S.Y., et al. In-patient and outpatient register of cardiovascular diseases in Ryazan Region (RECVASA): major tasks, formation experience, and first outcomes. Rational Pharmacotherapy in Cardiology. 2013;9(1):4-14 (In Russ.) DOI:10.20996/1819-6446-20139-1-4-14.

11. Yusuf S., Islam S., Chow C.K., et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey Lancet. 2011;378(9798):1231-43. DOI:10.1016/S01406736(11)61215-4.

12. Martsevich S.Y., Gaysenok O.V., Tripkosh S.G., et al. Medical supervision in specialized center and the quality of lipid-lowering therapy in patients with cardiovascular diseases (according to the PROFILE register). Rational Pharmacotherapy in Cardiology. 2013;9(2):133-7 (In Russ.) DOI:10.20996/1819-6446-2013-9-2-133-137.

13. Martsevich S.Y, Navasardian A.R, Kutishenko N.P., et al. Studying atrial fibrillation on the basis of the «PROFILE» registry. Cardiovascular Therapy and Prevention. 2014;13(2):35-9 (In Russ.) DOI:10.15829/1728-8800-2014-2-35-39.

14. Voronina V.P., Kisseleva N.V., Martsevich S.Y. Exercise tests in cardiology: past, present and future (Part I). Cardiovascular Therapy and Prevention. 2015;14(2):80-87 (In Russ DOI:10.15829/1728-8800-2015-2-80-87.

15. Sicari R., Nihoyannopoulos P., Evangelista A., et al.Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC).European Journal of Echocardiography. 2008;9(4):415-37. DOI:10.1093/ejechocard/jen175.

16. Catapano A.L., Graham I., De Backer G., et al. 2016 ESC/EAS Guidelines fr the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. DOI:10.1093/eurheartj/ehw272.

17. Martsevich S.Y., Lukina Y.V., Kutishenko N.P., et al. Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study). Rational Pharmacotherapy in Cardiology. 2019;15(6):864-72 (In Russ.) DOI:10.20996/1819-6446-2019-15-6-864-872.

18. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. Can J Cardiol. 2002;18(4):371-9.

19. Knuuti J., Wijns W., Saraste A., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. DOI:10.1093/eurheartj/ehz425.


For citation:


Martsevich S.Y., Zharkova E.D., Kutishenko N.P., Lukina Y.V., Tolpygina S.N., Voronina V.P., Zagrebelnyy A.V. An Attempt to Accord the Quality of Therapy of Stable Coronary Heart Disease Patients with Current Clinical Guidelines (ALIGN study): Design and the First Results. Rational Pharmacotherapy in Cardiology. 2020;16(1):75-81. (In Russ.) https://doi.org/10.20996/1819-6446-2020-02-08

Views: 87


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)